CRSP

CRISPR Therapeutics

Biotech · 9 tracked clinical trials

Clinical Pipeline

TrialPhaseStatusIndication
NCT04208529 PHASE3 ENROLLING_BY_INVITATION Beta-Thalassemia, Thalassemia, Sickle Cell Disease
NCT05356195 PHASE3 ACTIVE_NOT_RECRUITING Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn
NCT05329649 PHASE3 ACTIVE_NOT_RECRUITING Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance
NCT07549698 PHASE1, PHASE2 RECRUITING Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
NCT05643742 PHASE1, PHASE2 RECRUITING B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
NCT07758634 PHASE1, PHASE2 RECRUITING Hypertension
NCT06925542 PHASE1 RECRUITING SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis
NCT07491172 PHASE1 RECRUITING Cardiovascular, Metabolic Disease, Dyslipidemias
NCT06208878 ENROLLING_BY_INVITATION Hematologic Malignancy, Solid Malignancy

Partnerships & Collaborations

PartnerTypeAnnouncedDetails
No partnerships tracked yet.

Recent news

DateHeadlineSource
2026-08-31 CRISPR Therapeutics' (CRSP) Market Outperform Rating Reiterated at Citizens Jmp - MarketBeat Google News
2026-08-31 H.C. Wainwright reiterates CRISPR Therapeutics stock rating at buy - Investing.com Google News
2026-08-31 H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP) - StreetInsider Google News
2026-08-31 CRISPR Therapeutics (NASDAQ:CRSP) Earns Buy Rating from Needham & Company LLC - MarketBeat Google News
2026-08-30 CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data - simplywall.st Google News
2026-08-30 CRISPR Therapeutics cuts LDL cholesterol by half with one gene edit, lasting 1 year - DongA Science Google News
2026-08-30 Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair - The Globe and Mail Google News
2026-08-29 An Experimental One-Time Treatment for High Cholesterol Shows Promising Results - Time Magazine Google News
2026-08-28 Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year - Cleveland Clinic Newsroom Google News
2026-08-28 #ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy - endpoints.news Google News
2026-08-28 An Experimental Single-Time Treatment Slashed Cholesterol for a Year - The New York Times Google News
2026-08-28 News: CMN Weekly (28 August 2026) - Your Weekly CRISPR Medicine News - CRISPR Medicine News Google News
2026-08-28 CRISPR Therapeutics Presents Phase 1a Data for CTX310® - GlobeNewswire Google News
2026-08-28 CRISPR Therapeutics AG Presents Phase 1A Data for Ctx310 Demonstrating Deep and Durable Angptl3 Editing, Triglyceride and LDL Lowering - marketscreener.com Google News
2026-08-28 CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 - lincolnjournal.com Google News
2026-08-28 CRISPR Therapeutics reports one-year data for gene therapy CTX310 - Investing.com India Google News
2026-08-28 CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 - Yahoo Finance Google News
2026-08-28 CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 - Barchart.com Google News
2026-08-28 Clinical: Single CRISPR Infusion Keeps Lipids Low for a Year - CRISPR Medicine News Google News
2026-08-27 CRISPR Therapeutics (CRSP) Is Up 15.0% After Casgevy Label Expansion - What's Changed - Sahm Google News